Edition:
United States

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

4.17USD
8 Dec 2017
Change (% chg)

$-0.02 (-0.48%)
Prev Close
$4.19
Open
$4.23
Day's High
$4.30
Day's Low
$4.14
Volume
48,541
Avg. Vol
61,531
52-wk High
$5.67
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy
Wednesday, 16 Aug 2017 08:00am EDT 

Aug 16 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy.Fate Therapeutics Inc - patent covering use of prostaglandins as viral transduction enhancers for genetic modification of cd34hematopoietic cells​.Fate Therapeutics Inc - ‍patent expires in 2029, is owned by Indiana University research and technology corporand is licensed exclusively to co.  Full Article

Fate Therapeutics files for mixed shelf of upto $100 mln
Tuesday, 15 Aug 2017 05:42pm EDT 

Aug 15 (Reuters) - Fate Therapeutics Inc ::Fate Therapeutics Inc files for mixed shelf of upto $100 million - SEC filing.Fate Therapeutics Inc says in addition, selling stockholder may from time to time, offer and sell up to 1 million shares of common stock - SEC filing‍​.Fate Therapeutics Inc says it will not receive any of the proceeds from the sales of common stock from the selling stockholder‍​.  Full Article

Fate Therapeutics Q2 ‍net loss per common share $0.23​
Monday, 14 Aug 2017 04:01pm EDT 

Aug 14 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics reports second quarter 2017 financial results.Q2 revenue $1.0 million versus I/B/E/S view $937,000.Fate Therapeutics Inc - qtrly ‍net loss per common share, basic and diluted $0.23​.Q2 earnings per share view $-0.24, revenue view $936600.00 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics says FDA cleared third IND application for Fate-NK100​
Tuesday, 8 Aug 2017 11:59am EDT 

Aug 8 (Reuters) - Fate Therapeutics Inc ::Says ‍U.S. Food and Drug Administration cleared third Investigational New Drug (IND) application for Fate-NK100​.  Full Article

Fate Therapeutics to amend and restate loan and security agreement
Friday, 14 Jul 2017 04:26pm EDT 

July 14 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics Inc - on July 14, 2017 co entered into first amendment to amended and restated loan and security agreement - SEC filing.Fate Therapeutics - SVB loan amendment amends certain amended and restated loan and security agreement between company and bank, dated as of July 30, 2014.Fate Therapeutics Inc - term loan matures on January 1, 2022.Fate Therapeutics - pursuant to SVB loan amendment, bank extended an additional term loan to company on July 14, 2017 in principal amount of $15 million.Fate Therapeutics Inc - from August 1, 2017 through January 1, 2019 company is required to make monthly payments of interest only.  Full Article

Fate Therapeutics reports Q1 loss per share of $0.24
Monday, 15 May 2017 04:01pm EDT 

May 15 (Reuters) - Fate Therapeutics Inc :Reports first quarter 2017 financial results.Q1 revenue $1.0 million versus I/B/E/S view $947,000.Qtrly net loss per common share, basic and diluted $0.24.Research and development expenses were $8.0 million for Q1 of 2017 compared to $6.6 million for comparable period in 2016.  Full Article

Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100
Wednesday, 10 May 2017 08:00am EDT 

May 10 (Reuters) - Fate Therapeutics Inc :Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 in advanced solid tumors.  Full Article

Fate Therapeutics qtrly net loss per common share $ 0.21
Thursday, 16 Mar 2017 04:01pm EDT 

Fate Therapeutics Inc : Fate Therapeutics reports fourth quarter 2016 financial results . Q4 revenue $1.0 million versus I/B/E/S view $958,000 . Qtrly net loss per common share $ 0.21 . Fate Therapeutics Inc - cash, cash equivalents and short-term investments as of dec 31, 2016 were $92.1 million compared to $64.8 million as of dec 31, 2015 .Q4 earnings per share view $-0.29, revenue view $957500.00 -- Thomson Reuters I/B/E/S.  Full Article

Fate Therapeutics says investigational new drug application for its cancer drug gets FDA clearance
Monday, 13 Mar 2017 08:00am EDT 

Fate Therapeutics Inc - : Fate Therapeutics announces FDA clearance of investigational new drug application for FATE-NK100 natural killer cell cancer immunotherapy .Fate Therapeutics -expects a first-in-human clinical trial of fate-nk100 for aml to open enrollment at masonic cancer center, university of Minnesota.  Full Article

Fate Therapeutics files to say resale of up to 20.9 mln shares of common
Wednesday, 25 Jan 2017 05:07pm EST 

Fate Therapeutics Inc :Fate Therapeutics - files to say resale of up to 20.9 million shares of common stock by the selling stockholders named.  Full Article

BRIEF-Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy

* Fate Therapeutics announces issuance of U.S. patent covering use of viral transduction enhancers in gene therapy